Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 2/20 | 0.30 |
| ▸ | KDR | P35968 | 2/20 | 0.30 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
| ▸ | YES1 | P07947 | 1/20 | 0.30 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.30 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.30 |
| ▸ | LTK | P29376 | 1/20 | 0.30 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | MST1R | Q04912 | 1/20 | 0.30 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.30 |
| ▸ | VNN1 | O95497 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2797787 | 0.82 | — | — | |
| SCHEMBL2795244 | 0.81 | KMT2A (0.30) | KMT2A | |
| SCHEMBL2795900 | 0.81 | TGFBR1 (0.34) | TGFBR1KMT2A | |
| SCHEMBL13262439 | 0.81 | LOXL2 (0.32) | — | |
| SCHEMBL2799982 | 0.80 | NR3C1 (0.33) | KMT2AVNN1 | |
| SCHEMBL2796960 | 0.77 | GABRA1 (0.34) | LCK | |
| SCHEMBL13262444 | 0.76 | KMT2A (0.37) | KMT2AVNN1 | |
| SCHEMBL2793819 | 0.74 | — | — | |
| SCHEMBL2793624 | 0.74 | KMT2A (0.31) | KMT2AVNN1 | |
| SCHEMBL2797367 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2204365-A1 | ALKYLSULFONE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-07-07 | — | — | EP | disclosed |
| US-20100168136-A1 | ALKYLSULFONE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168136-A1 | ALKYLSULFONE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168136-A1 | ALKYLSULFONE DERIVATIVES | BACE1, APP, AMY1A | TGFBR1 1806/4885KMT2A 4719/4885MET 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.